Interaction Checker

Bortezomib interactions

Bortezomib (Velcade) has 204 documented interactions across the FDA labels and fact sheets we index: 33 major, 163 moderate, 5 minor, and 3 where a label reports no significant interaction. Each entry below quotes the sentence behind it. This drug page is a starting point, not a verdict for your situation.

Interactions from the label

Major interactions (33)

  • AprepitantCYP3A4 inhibitorMajor

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib label, Drug interactions)

  • ArmodafinilCNS stimulantMajor

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib label, Drug interactions)

  • BosentanCYP3A4 inducerMajor

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib label, Drug interactions)

  • CarbamazepineanticonvulsantMajor

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib label, Drug interactions)

  • CenobamateanticonvulsantMajor

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib label, Drug interactions)

  • ClobazambenzodiazepineMajor

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib label, Drug interactions)

  • Deferasiroxiron supplementMajor

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib label, Drug interactions)

  • DexamethasonecorticosteroidMajor

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib label, Drug interactions)

  • EfavirenzantiretroviralMajor

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib label, Drug interactions)

  • Efavirenz, lamivudine, and tenofovirantiretroviralMajor

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib label, Drug interactions)

  • EslicarbazepineanticonvulsantMajor

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib label, Drug interactions)

  • EtravirineantiretroviralMajor

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib label, Drug interactions)

  • FosphenytoinanticonvulsantMajor

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib label, Drug interactions)

  • GriseofulvinantifungalMajor

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib label, Drug interactions)

  • Ketoconazoleazole antifungalMajor

    …caution with ketoconazole, and specifically, should not be used within at least 72 hours of treatment with ketoconazole Antineoplastics irinotecan dasatinib, lapatinib, nilotinib bortezomib, busulphan, docetaxel, erlotinib, imatinib, ixabepilone, paclitaxel, trimetrexate, vinca alkaloids Irinotecan: The potential increase in plasma concentrations of irinotecan… (Ketoconazole label, Drug interactions)

  • Lopinavir and ritonavirantiretroviralMajor

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib label, Drug interactions)

  • LorlatinibCYP3A4 inducerMajor

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib label, Drug interactions)

  • MitapivatCYP3A4 inducerMajor

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib label, Drug interactions)

  • MitotaneCYP3A4 inducerMajor

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib label, Drug interactions)

  • ModafinilCNS stimulantMajor

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib label, Drug interactions)

  • Nafcillinpenicillin antibioticMajor

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib label, Drug interactions)

  • NevirapineantiretroviralMajor

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib label, Drug interactions)

  • OxcarbazepineanticonvulsantMajor

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib label, Drug interactions)

  • PhenobarbitalbarbiturateMajor

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib label, Drug interactions)

  • Phentermine and topiramateCNS stimulantMajor

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib label, Drug interactions)

  • PhenytoinanticonvulsantMajor

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib label, Drug interactions)

  • PrimidoneanticonvulsantMajor

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib label, Drug interactions)

  • RifabutinantibioticMajor

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib label, Drug interactions)

  • RifampinantibioticMajor

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib label, Drug interactions)

  • RifapentineantibioticMajor

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib label, Drug interactions)

  • RitonavirantiretroviralMajor

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib label, Drug interactions)

  • SuzetrigineCYP3A4 inducerMajor

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib label, Drug interactions)

  • TopiramateanticonvulsantMajor

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib label, Drug interactions)

Moderate interactions (163)

  • Acebutololbeta blockerModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Albuterolbeta-adrenergic agonistModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • AliskirenantihypertensiveModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Amiloridepotassium-sparing diureticModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • AmiodaroneantiarrhythmicModerate

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib label, Drug interactions)

  • Amlodipinedihydropyridine calcium channel blockerModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Amlodipine and atorvastatindihydropyridine calcium channel blockerModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Amlodipine and benazeprildihydropyridine calcium channel blockerModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Amlodipine and olmesartandihydropyridine calcium channel blockerModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Amlodipine and valsartandihydropyridine calcium channel blockerModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • AmphetamineCNS stimulantModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • Amphetamine and dextroamphetamineCNS stimulantModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • Arformoterolbeta-adrenergic agonistModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • Articaine and epinephrinelocal anestheticModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • AtazanavirantiretroviralModerate

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib label, Drug interactions)

  • Atenololbeta blockerModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Atenolol and chlorthalidonebeta blockerModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Azilsartanangiotensin II receptor blocker (ARB)Moderate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • BenazeprilACE inhibitorModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Benazepril and hydrochlorothiazideACE inhibitorModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • BenzphetamineCNS stimulantModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • Betaxololbeta blockerModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Bisoprololbeta blockerModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Bisoprolol and hydrochlorothiazidebeta blockerModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Brompheniramine, pseudoephedrine, and dextromethorphanantihistamineModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • Budesonide and formoterolcorticosteroidModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • Bupivacaine and epinephrinelocal anestheticModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • Butalbital, acetaminophen, and caffeinebarbiturateModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • Butalbital, acetaminophen, caffeine, and codeinebarbiturateModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • Butalbital, aspirin, and caffeinebarbiturateModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • Butalbital, aspirin, caffeine, and codeinebarbiturateModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • Candesartanangiotensin II receptor blocker (ARB)Moderate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Candesartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)Moderate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • CaptoprilACE inhibitorModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Carvedilolbeta blockerModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Chlorothiazidethiazide diureticModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Chlorthalidonethiazide diureticModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • CimetidineH2 blockerModerate

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib label, Drug interactions)

  • Clarithromycinmacrolide antibioticModerate

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib label, Drug interactions)

  • Clonidinealpha-adrenergic agonistModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • CyclosporineimmunosuppressantModerate

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib label, Drug interactions)

  • CytarabineantimetaboliteModerate

    In a clinical trial, the first two patients given high-dose cytarabine (2 g/m 2 per day) by continuous infusion with daunorubicin and bortezomib for relapsed acute myelogenous leukemia died of ARDS early in the course of therapy. (Bortezomib label, Warnings and precautions)

  • DarunavirantiretroviralModerate

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib label, Drug interactions)

  • Darunavir and cobicistatantiretroviralModerate

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib label, Drug interactions)

  • DaunorubicinModerate

    In a clinical trial, the first two patients given high-dose cytarabine (2 g/m 2 per day) by continuous infusion with daunorubicin and bortezomib for relapsed acute myelogenous leukemia died of ARDS early in the course of therapy. (Bortezomib label, Warnings and precautions)

  • DexmethylphenidateCNS stimulantModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • DextroamphetamineCNS stimulantModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • DiethylpropionCNS stimulantModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • Diltiazemcalcium channel blockerModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • DobutaminesympathomimeticModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • Doxazosinalpha blockerModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • DronedaroneantiarrhythmicModerate

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib label, Drug interactions)

  • DroxidopasympathomimeticModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • Elvitegravir, cobicistat, emtricitabine, and tenofovirantiretroviralModerate

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib label, Drug interactions)

  • EnalaprilACE inhibitorModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Enalapril and hydrochlorothiazideACE inhibitorModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • EnalaprilatACE inhibitorModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • EphedrinesympathomimeticModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • EpinephrinesympathomimeticModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • Eplerenonealdosterone antagonistModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Ergotamine and caffeineergot alkaloidModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • Erythromycinmacrolide antibioticModerate

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib label, Drug interactions)

  • Ethacrynic acidloop diureticModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • EverolimusimmunosuppressantModerate

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib label, Drug interactions)

  • Felodipinedihydropyridine calcium channel blockerModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Fluconazoleazole antifungalModerate

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib label, Drug interactions)

  • FludrocortisonecorticosteroidModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • Fluticasone and salmeterolcorticosteroidModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • Formoterolbeta-adrenergic agonistModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • FosamprenavirantiretroviralModerate

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib label, Drug interactions)

  • FosaprepitantCYP3A4 inhibitorModerate

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib label, Drug interactions)

  • FosinoprilACE inhibitorModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Fosinopril and hydrochlorothiazideACE inhibitorModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Furosemideloop diureticModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Guanfacinealpha-adrenergic agonistModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • HydralazinevasodilatorModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Hydrochlorothiazidethiazide diureticModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • ImatinibCYP3A4 inhibitorModerate

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib label, Drug interactions)

  • Indapamidethiazide diureticModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Ipratropium and albuterolanticholinergicModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • Irbesartanangiotensin II receptor blocker (ARB)Moderate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Irbesartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)Moderate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • IsoniazidantibioticModerate

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib label, Drug interactions)

  • Isoproterenolbeta-adrenergic agonistModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • Isosorbide dinitrate and hydralazinenitrateModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Isradipinedihydropyridine calcium channel blockerModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Itraconazoleazole antifungalModerate

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib label, Drug interactions)

  • IvacaftorCYP3A4 inhibitorModerate

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib label, Drug interactions)

  • Labetalolbeta blockerModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • LenacapavirantiretroviralModerate

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib label, Drug interactions)

  • Levalbuterolbeta-adrenergic agonistModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • Lidocaine and epinephrinelocal anestheticModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • LisdexamfetamineCNS stimulantModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • LisinoprilACE inhibitorModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Lisinopril and hydrochlorothiazideACE inhibitorModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Lofexidinealpha-adrenergic agonistModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Losartanangiotensin II receptor blocker (ARB)Moderate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Losartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)Moderate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • MecamylamineantihypertensiveModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • MethamphetamineCNS stimulantModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • MethyldopaantihypertensiveModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • MethylphenidateCNS stimulantModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • Metolazonethiazide diureticModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Metoprololbeta blockerModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Metoprolol and hydrochlorothiazidebeta blockerModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Midodrinealpha-adrenergic agonistModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • MifepristoneCYP3A4 inhibitorModerate

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib label, Drug interactions)

  • MinoxidilvasodilatorModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Mirabegronbeta-adrenergic agonistModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • MoexiprilACE inhibitorModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Nadololbeta blockerModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Nebivololbeta blockerModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • NefazodoneantidepressantModerate

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib label, Drug interactions)

  • Nicardipinedihydropyridine calcium channel blockerModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Nifedipinedihydropyridine calcium channel blockerModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Nirmatrelvir and ritonavirantiviralModerate

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib label, Drug interactions)

  • Nisoldipinedihydropyridine calcium channel blockerModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • NitroprussidevasodilatorModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Olmesartanangiotensin II receptor blocker (ARB)Moderate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Olmesartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)Moderate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Olmesartan, amlodipine, and hydrochlorothiazideangiotensin II receptor blocker (ARB)Moderate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Orphenadrine, aspirin, and caffeinemuscle relaxantModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • OxymetazolinedecongestantModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • PalbociclibCYP3A4 inhibitorModerate

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib label, Drug interactions)

  • PerampanelanticonvulsantModerate

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib label, Drug interactions)

  • PerindoprilACE inhibitorModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • PhendimetrazineCNS stimulantModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • Phenoxybenzaminealpha blockerModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • PhentermineCNS stimulantModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • PhenylephrinedecongestantModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • Pindololbeta blockerModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Posaconazoleazole antifungalModerate

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib label, Drug interactions)

  • Prazosinalpha blockerModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Prilocaine and epinephrinelocal anestheticModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • Propranololbeta blockerModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • PseudoephedrinedecongestantModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • QuinaprilACE inhibitorModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Quinapril and hydrochlorothiazideACE inhibitorModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • RamiprilACE inhibitorModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • RanolazineQT-prolonging drugModerate

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib label, Drug interactions)

  • Sacubitril and valsartanangiotensin II receptor blocker (ARB)Moderate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Salmeterolbeta-adrenergic agonistModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • SolriamfetolCNS stimulantModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • Spironolactonealdosterone antagonistModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Spironolactone and hydrochlorothiazidealdosterone antagonistModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Suvorexantsedative-hypnoticModerate

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib label, Drug interactions)

  • Telmisartanangiotensin II receptor blocker (ARB)Moderate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Telmisartan and amlodipineangiotensin II receptor blocker (ARB)Moderate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Telmisartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)Moderate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Terazosinalpha blockerModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Terbutalinebeta-adrenergic agonistModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • Ticagrelorantiplatelet agentModerate

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib label, Drug interactions)

  • Tizanidinemuscle relaxantModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Torsemideloop diureticModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • TrandolaprilACE inhibitorModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Triamterenepotassium-sparing diureticModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Triamterene and hydrochlorothiazidepotassium-sparing diureticModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Umeclidinium and vilanterolanticholinergicModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • Valsartanangiotensin II receptor blocker (ARB)Moderate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Valsartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)Moderate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Verapamilcalcium channel blockerModerate

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib label, Warnings and precautions)

  • Vibegronbeta-adrenergic agonistModerate

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib label, Warnings and precautions)

  • Voriconazoleazole antifungalModerate

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib label, Drug interactions)

Minor mentions (5)

  • CyclophosphamideimmunosuppressantMinor

    …* A baseline platelet count of 50,000/μL was required for study eligibility ‡ Data were missing at baseline for one patient In the combination study of bortezomib with rituximab, cyclophosphamide, doxorubicin and prednisone (BR-CAP) in previously untreated mantle cell lymphoma patients, the incidence of thrombocytopenia (≥ Grade 4) was 32% vs 1% for the rituximab,… (Bortezomib label, Warnings and precautions)

  • DoxorubicinMinor

    …platelet count of 50,000/μL was required for study eligibility ‡ Data were missing at baseline for one patient In the combination study of bortezomib with rituximab, cyclophosphamide, doxorubicin and prednisone (BR-CAP) in previously untreated mantle cell lymphoma patients, the incidence of thrombocytopenia (≥ Grade 4) was 32% vs 1% for the rituximab, cyclophosphamide,… (Bortezomib label, Warnings and precautions)

  • PrednisonecorticosteroidMinor

    …50,000/μL was required for study eligibility ‡ Data were missing at baseline for one patient In the combination study of bortezomib with rituximab, cyclophosphamide, doxorubicin and prednisone (BR-CAP) in previously untreated mantle cell lymphoma patients, the incidence of thrombocytopenia (≥ Grade 4) was 32% vs 1% for the rituximab, cyclophosphamide, doxorubicin,… (Bortezomib label, Warnings and precautions)

  • RituximabimmunosuppressantMinor

    …(14%) 5 (71%) * A baseline platelet count of 50,000/μL was required for study eligibility ‡ Data were missing at baseline for one patient In the combination study of bortezomib with rituximab, cyclophosphamide, doxorubicin and prednisone (BR-CAP) in previously untreated mantle cell lymphoma patients, the incidence of thrombocytopenia (≥ Grade 4) was 32% vs 1% for… (Bortezomib label, Warnings and precautions)

  • VincristineMinor

    …baseline for one patient In the combination study of bortezomib with rituximab, cyclophosphamide, doxorubicin and prednisone (BR-CAP) in previously untreated mantle cell lymphoma patients, the incidence of thrombocytopenia (≥ Grade 4) was 32% vs 1% for the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) arm as shown in Table 12 . (Bortezomib label, Warnings and precautions)

No significant interaction reported (3)

  • MelphalanNo interaction

    Drugs Without Clinically Significant Interactions with Bortezomib No clinically significant drug interactions have been observed when bortezomib was coadministered with dexamethasone, omeprazole, or melphalan in combination with prednisone [see Clinical Pharmacology (12.3) ] . (Bortezomib label, Drug interactions)

  • Omeprazoleproton pump inhibitorNo interaction

    Drugs Without Clinically Significant Interactions with Bortezomib No clinically significant drug interactions have been observed when bortezomib was coadministered with dexamethasone, omeprazole, or melphalan in combination with prednisone [see Clinical Pharmacology (12.3) ] . (Bortezomib label, Drug interactions)

  • Omeprazole and sodium bicarbonateproton pump inhibitorNo interaction

    Drugs Without Clinically Significant Interactions with Bortezomib No clinically significant drug interactions have been observed when bortezomib was coadministered with dexamethasone, omeprazole, or melphalan in combination with prednisone [see Clinical Pharmacology (12.3) ] . (Bortezomib label, Drug interactions)

Check Bortezomib against everything you take. Add your full list; every pair is checked at once.

Open in the checker

Not medical advice. Severity reflects the label's wording, not your circumstances. A "major" flag can be routine under supervision and a "minor" one can matter at high doses. Ask a pharmacist.